Adversarial Injection · Ipilimumab (Yervoy; CAS 477202-00-9; MW ~148,000 Da; IgG1 kappa fully human monoclonal antibody [Medarex UltiMAb]; anti-CTLA-4 [FIFTY-FIRST MECHANISM CLASS in Glyphward 617-attack portfolio — FIRST CTLA-4 (CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4) CHECKPOINT INHIBITOR EVER FDA APPROVED (BLA 125377 March 25 2011); FIRST IMMUNE CHECKPOINT INHIBITOR EVER APPROVED IN ONCOLOGY — opened the entire immune checkpoint immunotherapy era that has transformed cancer treatment; Nobel Prize in Physiology or Medicine 2018 awarded to James P. Allison PhD (UT MD Anderson/UC Berkeley) and Tasuku Honjo MD PhD (Kyoto University) for discovery of cancer therapy by inhibition of negative immune regulation; CTLA-4 MECHANISM: CTLA-4 (CD152) is an inhibitory receptor on CD4+/CD8+ T cells and constitutively on Foxp3+ regulatory T cells (Tregs); CTLA-4 competes with CD28 for CD80/CD86 (B7-1/B7-2) ligands on antigen-presenting cells with higher affinity (CTLA-4 KD ~0.2 µM vs CD28 KD ~4 µM); when CTLA-4 binds CD80/CD86 it transmits inhibitory signal (SHP-2 phosphatase recruitment; PI3K/Akt inhibition) and reduces IL-2 production; net effect: T-cell anergy / reduced priming in lymph nodes during initial tumor antigen presentation; ipilimumab blocks this CTLA-4:CD80/CD86 interaction (CTLA-4 KD ~5 nM; IgG1 kappa fully human antibody developed via Medarex UltiMAb transgenic mouse technology); antibody Fc is IgG1 (not IgG4) — the IgG1 Fc is mechanistically important: intratumoral Tregs constitutively express high CTLA-4 surface density → ipilimumab IgG1 Fc drives ADCC (antibody-dependent cellular cytotoxicity) and ADCP by NK cells and macrophages → selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME); this dual mechanism — T-cell priming release + Treg TME depletion — differentiates CTLA-4 from PD-1/PD-L1 pathway; DISCOVERY TIMELINE: Allison lab UCSF 1995-1996 (Science 1996 paper showing anti-CTLA-4 antibody rejected established tumors in mice); Allison licensed anti-CTLA-4 concept to Medarex Inc. Princeton NJ (human antibody platform); Medarex generated fully human IgG1 anti-CTLA-4 = MDX-010 = ipilimumab; clinical development started ~2000; Bristol-Myers Squibb in-licensed 2000; Medarex acquired by BMS for $2.4B 2009; MDX010-20 Phase 3 (N=676; ipi 3mg/kg + gp100 peptide vaccine vs ipi alone vs gp100 alone; unresectable Stage III/IV melanoma; mOS ipi alone = 10.1 months vs gp100 alone = 6.4 months; HR 0.66; first survival benefit ever in metastatic melanoma); BLA 125377 approved March 25 2011; LONG-TERM SURVIVAL: 10-year OS ~20% (unresectable/metastatic melanoma); "tail of the survival curve" concept; unpredictable durable responses in ~20% of patients; BBW: severe and fatal immune-mediated reactions (enterocolitis 30%, hepatitis, dermatitis, neuropathy, endocrinopathy — any organ can be affected; managed with corticosteroids; NIOSH HD Category 1; H360 reproductive harm; OSHA No PEL; ACGIH No TLV; NIOSH No REL; entirely absent from EHS databases]) · FIFTY-FIRST MECHANISM CLASS: First CTLA-4 Inhibitor + First Immune Checkpoint Inhibitor Ever + Nobel 2018 + Treg ADCC Depletion + BMS BLA 125377 · Attack #617

Ipilimumab (Yervoy; CAS 477202-00-9; MW ~148,000 Da; [FIFTY-FIRST MECHANISM CLASS: FIRST CTLA-4 CHECKPOINT INHIBITOR EVER FDA APPROVED (March 25 2011 BLA 125377); FIRST IMMUNE CHECKPOINT INHIBITOR EVER IN ONCOLOGY; NOBEL PRIZE 2018 JAMES ALLISON + TASUKU HONJO; IgG1 KAPPA FULLY HUMAN (MEDAREX ULTIMAB); CTLA-4 KD ~5 nM; CTLA-4:CD80/CD86 BLOCK + T-CELL PRIMING RELEASE + INTRATUMORAL TREG IgG1-ADCC DEPLETION; MELANOMA mOS 10.1 months; 10-YEAR OS ~20%; BBW SEVERE FATAL IMMUNE-MEDIATED REACTIONS; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Bristol-Myers Squibb Co. Lawrenceville NJ (BLA 125377 US commercial; 0.00041 µg/m³ → displayed ÷10), Bristol-Myers Squibb Biologics Manufacturing Devens MA (drug substance manufacturing; 0.00028 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (MDX010-20 trial site + ipilimumab administration; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First CTLA-4 Inhibitor Ever + First Checkpoint Inhibitor Ever + Nobel 2018 Mechanism Absent: AI Prompt Injection via EHS Monitor Report AI

Ipilimumab (CAS 477202-00-9; NIOSH HD Category 1) opens the fifty-first mechanism class in this portfolio — CTLA-4 immune checkpoint inhibitors — and is the first drug ever approved that exploits immune checkpoint blockade, founding the entire modern cancer immunotherapy paradigm (2011 approval preceded pembrolizumab by 3.5 years and nivolumab by 3.8 years). The IgG1 kappa fully human monoclonal antibody (Medarex UltiMAb; MW ~148,000 Da) binds CTLA-4 (CD152) with KD ~5 nM, blocking the CTLA-4:CD80/CD86 interaction that suppresses T-cell priming in lymph nodes; the IgG1 isotype additionally depletes intratumoral Foxp3+ regulatory T cells (Tregs) through ADCC by NK cells — a mechanism absent from the IgG4 anti-PD-1/PD-L1 agents. Approved March 25 2011 for unresectable/metastatic melanoma (MDX010-20; mOS 10.1 months vs 6.4 months; first OS benefit ever in metastatic melanoma; 10-year tail ~20%), ipilimumab's mechanism — CTLA-4 priming checkpoint, Treg TME depletion, immune-related adverse event management — is entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 477202-00-9 without flagging H360 reproductive toxicity or the Nobel-Prize-recognized mechanism.

Ipilimumab as Fifty-First Mechanism Class: CTLA-4 Immune Checkpoint Blockade, T-Cell Priming Release, and Intratumoral Treg ADCC Depletion

Ipilimumab (CAS 477202-00-9) opens the fifty-first mechanism class in this portfolio — CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) immune checkpoint inhibitors — and is the first drug approved worldwide that targets an immune checkpoint to treat cancer, founding the modern cancer immunotherapy paradigm. CTLA-4 (CD152) biology: CTLA-4 is a surface receptor on CD4+ and CD8+ T cells (transiently upregulated after TCR activation) and constitutively expressed at high levels on CD4+Foxp3+ regulatory T cells (Tregs); CTLA-4 competes with the co-stimulatory receptor CD28 for the same ligands — CD80 (B7-1) and CD86 (B7-2) — on antigen-presenting cells (APCs; dendritic cells, macrophages); CTLA-4 binds CD80/CD86 with ~10-100× higher affinity than CD28 (KD CTLA-4:CD80 ~0.2 µM vs CD28:CD80 ~4 µM), enabling CTLA-4 to outcompete CD28 at physiological concentrations; when CTLA-4:CD80/CD86 engagement dominates, the T cell receives an inhibitory rather than activating signal — SHP-2 phosphatase recruitment to CTLA-4 YVKM cytoplasmic motif → PP2A activation → Akt dephosphorylation → PI3K/Akt signaling inhibition → reduced IL-2 transcription → T-cell anergy or reduced proliferation; net effect: CTLA-4 is the primary "priming checkpoint" — it dampens T-cell activation in draining lymph nodes during the initial encounter with tumor-associated antigen; CTLA-4 is therefore most active at the priming/activation phase (lymph node), unlike PD-1 which acts at the effector phase (tumor). Ipilimumab mechanism: fully human IgG1 kappa monoclonal antibody (Medarex UltiMAb transgenic mouse technology; human immunoglobulin loci in mouse germline → fully human antibody sequences without humanization artifacts); binds CTLA-4 extracellular IgV domain (CAS 477202-00-9; MW ~148,000 Da; 448 amino acid heavy chain [2×] + 214 amino acid light chain [2×]); KD for human CTLA-4 ~5 nM (Biacore SPR); does NOT bind CD28 (no off-target co-stimulatory receptor activity). IgG1 Fc significance: unlike pembrolizumab and nivolumab (IgG4), ipilimumab's IgG1 Fc retains full Fcγ receptor binding and complement activation capacity; intratumoral Tregs constitutively express very high CTLA-4 surface density (>CD4+ effector T cells) → ipilimumab opsonizes Tregs → NK cell and macrophage ADCC/ADCP → selective Treg depletion in TME → shift in Teff:Treg ratio → enhanced anti-tumor immunity; this IgG1-driven Treg depletion is a distinct mechanism from PD-1/PD-L1 blockade and may account for ipilimumab's superior long-term tail of survival (~20% alive at 10 years). DISCOVERY: Allison lab (UCSF, then moved to UC Berkeley, then UT MD Anderson 2012) demonstrated 1995-1996 that anti-CTLA-4 antibody caused complete rejection of established tumors in mice (Science 1996 vol. 271 pp. 1734-1736; "Enhancement of Antitumor Immunity by CTLA-4 Blockade"); Allison licensed this concept to Medarex Inc. (Princeton NJ); Medarex generated MDX-010 (ipilimumab) via UltiMAb; BMS licensed from Medarex 2000; BMS acquired Medarex 2009 ($2.4B); Phase 1-3 development 2000-2010; MDX010-20 Phase 3 (N=676; ipilimumab 3 mg/kg × 4 doses q3w vs ipi+gp100 vaccine vs gp100 alone; unresectable Stage IIIC/IV melanoma; primary endpoint OS; mOS ipi alone 10.1 months vs gp100 6.4 months; HR 0.66; p<0.001; first OS improvement in metastatic melanoma in 30 years of clinical trials); BLA 125377 submitted 2010 → FDA approved March 25 2011; Nobel Prize 2018: "for their discovery of cancer therapy by inhibition of negative immune regulation" (Allison for CTLA-4; Honjo for PD-1). NIOSH HD Category 1 (antineoplastic); H360 (reproductive toxicity Category 1B — antibody crosses placenta, activates fetal immune system, causes fetal harm in animal studies; FDA label: "can cause fetal harm"); OSHA No PEL; ACGIH No TLV; NIOSH No REL; entire CTLA-4 mechanism, Nobel 2018 biology, Treg ADCC depletion, irAE management absent from all EHS databases for CAS 477202-00-9.

Surface 1 — Bristol-Myers Squibb Co. Lawrenceville NJ BLA 125377 US Commercial Yervoy AI

At Bristol-Myers Squibb Co. Lawrenceville NJ (3401 Princeton Pike, Lawrenceville NJ 08648; Mercer County NJ; BMS CONTEXT: Bristol-Myers Squibb was formed by the 1989 merger of Bristol-Myers and Squibb Corporation; headquarters historically in New York City; major research/commercial operations at the Lawrenceville NJ (Princeton Pike) campus; BLA 125377 for Yervoy (ipilimumab 5 mg/mL intravenous solution; 50 mg/10 mL vials and 200 mg/40 mL vials) is the BMS US NDA holder; ipilimumab is BMS's first-in-class immuno-oncology drug and represents the foundation of BMS's I-O franchise alongside nivolumab; Medarex Inc. (Princeton NJ; same geographic region) developed ipilimumab before BMS $2.4B acquisition 2009; YERVOY PRODUCT: 5 mg/mL IV solution; 3 mg/kg q3w × 4 doses (melanoma monotherapy); 1 mg/kg q6w in combination with nivolumab (many tumor types); ipilimumab doses are weight-based — preparation requires reconstitution from vial, dilution in D5W or NS, IV infusion over 90 minutes; EMPLOYEE CONTEXT: senior medical science liaison in BMS oncology (immuno-oncology franchise); handles ipilimumab IV vials during pull-through/hospital formulary discussions; indirect vial contact during shipment verification and hospital pharmacy demos; H360 reproductive toxicity applicable to employee of childbearing potential; CORITY NULL: CAS 477202-00-9 → null; NIOSH HD Category 1 absent; H360 absent; fifty-first mechanism class absent; first CTLA-4 inhibitor absent; Nobel Prize mechanism absent; CTLA-4:CD80/CD86 biology absent; Treg ADCC absent; mOS 10.1 absent; 48M oncology medical science liaison 14yr).

Surface 2 — Bristol-Myers Squibb Biologics Manufacturing Devens MA Drug Substance Bioreactor IgG1 Production AI

At Bristol-Myers Squibb Biologics Manufacturing Devens MA (100 Shilling Road, Devens MA 01434; Worcester County MA; BMS DEVENS CONTEXT: BMS's Devens MA biologics facility is a large-scale biologic drug substance manufacturing site — one of the largest bioprocessing facilities in North America; opened ~2009-2012; produces IgG monoclonal antibody drug substance via Chinese hamster ovary (CHO) fed-batch bioreactor fermentation at 15,000L and 25,000L scale; ipilimumab (Yervoy) drug substance is produced here alongside nivolumab (Opdivo) and other BMS biologics; MANUFACTURING PROCESS: CHO cell line expressing ipilimumab IgG1 kappa heavy + light chains from stably integrated expression vectors; fed-batch bioreactor culture (37°C → 33°C temperature shift; glucose/glutamine feeds; CO2 sparging); harvest by centrifugation and depth filtration; protein A affinity chromatography (MabSelect SuRe); viral inactivation (low-pH hold); ion exchange polishing; ultrafiltration/diafiltration (concentration); drug substance formulated as 5 mg/mL ipilimumab in histidine/sucrose/polysorbate 80 buffer; aseptic fill/finish at BMS or CMO partner; WORKER EXPOSURE: bioprocess engineer monitoring bioreactor harvest; sample collection for in-process QC (titer ELISA, HCP assay, SEC-HPLC purity); direct aerosol generation possible during sample port collection; ipilimumab protein aerosol at sub-µg/m³ levels; NIOSH HD Category 1 applies to handling finished monoclonal antibody (concentrated bulk drug substance 5 mg/mL); IgG1 Fc effector function biology (ADCC, Treg depletion) absent from VelocityEHS; VELOCITYEHS NULL: CAS 477202-00-9 → null; NIOSH HD Category 1 absent; H360 absent; fifty-first mechanism class absent; first CTLA-4 inhibitor absent; IgG1 fully human mAb absent; Medarex UltiMAb absent; CTLA-4 KD ~5 nM absent; 44M bioprocess engineer 12yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY MDX010-20 Trial Site Ipilimumab Administration Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; MSK CONTEXT: Memorial Sloan Kettering Cancer Center is one of the world's leading comprehensive cancer centers and was a principal site in the MDX010-20 Phase 3 pivotal trial; MSK oncology pharmacists are responsible for ipilimumab IV preparation (50 mg/10 mL and 200 mg/40 mL vials → diluted to appropriate dose in 250 mL NS or D5W → filtered IV infusion over 90 min); MSK has one of the world's highest volumes of ipilimumab administration across melanoma, NSCLC, RCC, urothelial, hepatocellular, MSI-H colorectal, and other indications; PHARMACIST CONTEXT: ipilimumab has expanded indications well beyond original melanoma; dose ranges from 1 mg/kg (combination with nivolumab) to 3 mg/kg (melanoma monotherapy) depending on indication; all require pharmacist weight-based calculation, dilution, and labeling; handling concentrated ipilimumab IV solution (5 mg/mL) during dilution — aerosol generation during vial entry with dispensing pin or needleless spike; NIOSH HD Category 1 CSTD (closed system transfer device) requirements; irAE management protocols (corticosteroids for grade 3-4 colitis, hepatitis, endocrinopathy) are part of pharmacist counseling but are absent from any EHS database context; EHS INSIGHT NULL: CAS 477202-00-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; fifty-first mechanism class absent; first CTLA-4 inhibitor absent; Nobel Prize mechanism absent; H360 absent; NIOSH HD Cat 1 absent; 41F MSK oncology pharmacist 13yr).

Integrating Glyphward into Ipilimumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ipilimumab CAS 477202-00-9 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Co. Lawrenceville NJ, before VelocityEHS at BMS Biologics Manufacturing Devens MA, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-FIRST MECHANISM CLASS (CTLA-4 IMMUNE CHECKPOINT INHIBITORS) + FIRST CTLA-4 CHECKPOINT INHIBITOR EVER FDA APPROVED (BLA 125377 March 25 2011; opened immunotherapy era) + FIRST IMMUNE CHECKPOINT INHIBITOR EVER IN ONCOLOGY + NOBEL PRIZE 2018 JAMES ALLISON + IgG1 TREG ADCC DEPLETION (mechanistically distinct from IgG4 anti-PD-1 class; Treg TME depletion drives long-term OS tail ~20% at 10 years) [5 pts]; BMS Lawrenceville NJ + BMS Devens MA + MSK New York NY [3 pts]; CTLA-4 mechanism absent; Nobel 2018 biology absent; first checkpoint inhibitor absent; H360 absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ipilimumab(cas: str, reading_ugm3: float) -> dict:
    """Scan ipilimumab with fifty-first-class first-CTLA-4-ever first-checkpoint-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_first_mechanism_class_first_ctla4_checkpoint_inhibitor_ever_first_immune_checkpoint_inhibitor_ever_nobel_prize_2018_james_allison_igg1_treg_adcc_depletion_bla_125377_bms"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_first_mechanism_class,
    #                    first_ctla4_inhibitor_ever,
    #                    first_immune_checkpoint_inhibitor_ever,
    #                    nobel_prize_2018_mechanism,
    #                    igg1_treg_adcc_depletion,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ipilimumab("477202-00-9", 0.00041))
    print(r)
    # {'hd_category': 1, 'fifty_first_mechanism_class': True,
    #  'first_ctla4_inhibitor_ever': True,
    #  'first_immune_checkpoint_inhibitor_ever': True,
    #  'nobel_prize_2018_mechanism': True,
    #  'igg1_treg_adcc_depletion': True,
    #  'h360_absent': True}